STAGE III RENAL CELL CANCER AJCC V8
Clinical trials for STAGE III RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gut bacteria boost may help kidney cancer drugs work better
Disease control OngoingThis early-phase study looks at whether adding a probiotic called CBM588 to the usual two-drug treatment (cabozantinib and nivolumab) can improve outcomes for people with advanced kidney cancer that has spread. The probiotic is meant to increase helpful gut bacteria, which may he…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New combo shows promise in advanced kidney cancer trial
Disease control OngoingThis phase 3 trial tests whether adding the drug cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will take part. The goal is to see if the combination wor…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New combo therapy targets Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:46 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks, then have surgery. The main goal is t…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 11:45 UTC
-
New drug shrinks kidney tumors before surgery in early trial
Disease control OngoingThis study tests whether giving the drug cabozantinib before surgery can shrink tumors in people with locally advanced kidney cancer. About 22 participants will receive the drug for a short time before their operation. The goal is to see if this approach helps control the disease…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
New hope for kidney cancer: two drug regimens battle after immunotherapy fails
Disease control OngoingThis study tests two different drug treatments for people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of two drugs (lenvatinib plus everolimus) or a single drug (cabozantini…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
Could a tropical berry boost immunotherapy against kidney cancer?
Disease control OngoingThis early-stage trial tests whether adding camu camu, a prebiotic berry, to standard immunotherapy (nivolumab and ipilimumab) can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the combination. T…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
Targeted drug shows promise for rare genetic cancer type
Disease control OngoingThis study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack the SETD2 gene. The drug works by blocking enzymes that help cancer cells grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Personalized cell therapy trial for advanced cancers withdrawn before enrollment
Disease control TerminatedThis early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy shows promise for rare kidney cancer
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare type of kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial i…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Promising drug cocktail targets rare, aggressive kidney cancer
Disease control OngoingThis study tests a combination of three drugs (ixazomib, gemcitabine, and doxorubicin) in 30 people with a rare and aggressive kidney cancer that has spread. The goal is to see if the treatment can shrink tumors or stop them from growing. Participants receive the drugs in cycles,…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC